Cyprotex PLC Notice of AGM (7746Y)
May 19 2016 - 9:38AM
UK Regulatory
TIDMCRX
RNS Number : 7746Y
Cyprotex PLC
19 May 2016
19 May 2016
Cyprotex PLC
("Cyprotex" or the "Company" or the "Group")
Publication of Annual Report & Accounts 2015
& Notice of AGM
Cyprotex PLC announces that its 2015 Annual Report and Accounts
for the year ending 31 December 2015, together with the Notice of
the Annual General Meeting and associated proxy form will today be
posted to shareholders.
The 2015 Annual Report and Accounts are available from the
Company's website, www.cyprotex.com
Cyprotex PLC's Annual General Meeting will be held on Thursday
23 June 2015 at 10.00 a.m. at the offices of N+1 Singer Advisory
LLP, One Bartholomew Lane, London EC2N 2AX .
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20
Cyprotex) 7496 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors:
Cyprotex PLC
Cyprotex is quoted on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1400 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries. In 2015, Cyprotex launched its new bioscience division
to expand its capabilities into phenotypic and target based
screening. The Company's core capabilities include high quality in
vitro ADME services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling solutions including Cloe(R) PK, chemPK(TM) and
chemTox, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAXKLFFQEFXBBD
(END) Dow Jones Newswires
May 19, 2016 09:38 ET (13:38 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
